Healthcare
Rapport Therapeutics, Inc. Common Stock(RAPP)
Live Price
Offline$37.34
+1.27% today
1Y Change
+243.20%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.24B
- Revenue Growth
- 0.0%
- EPS Growth
- -652.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapport Therapeutics, Inc. Common Stock (RAPP) is a Healthcare stock with a market cap of $1.24B and listed on NASDAQ. The stock last traded around $37.34 and up 243.2% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -652.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -652.6%, free cash flow -31.0% with operating margin 0.0% and ROIC -25.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RAPP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -652.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.3% | -3.3% | +1.2% |
2026 Mar 10, 2026 | -10.8% | +3.1% | -6.4% | +13.7% |
2025 Nov 6, 2025 | +7.8% | +1.2% | -2.7% | +16.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAPP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RAPP Max Drawdown
-28.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RAPP and SPY.
Company Overview
Rapport Therapeutics, Inc. Common Stock
NASDAQ Global Market
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
- Leadership
- Abraham N. Ceesay
- IPO Date
- Jun 7, 2024
- Employees
- 69
- Street Address
- 1325 Boylston Street
- Mailing
- Boston, DE
- Region
- Boston, DE, US
- Reporting Currency
- USD
- Investor Line
- +1 617 945 0548
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.3
Growth
- Revenue
- 0.0%
- EPS
- -652.6%
- Free Cash Flow
- -31.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -28.9%
- ROIC
- -25.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 26.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.